Conferences - Results from #220

AUA 2022: Changes in Pituitary–Gonadal Hormones After Enzalutamide or Abiraterone Plus Prednisone in Men With Castration-Resistant Prostate Cancer (HEAT): Results From a Randomised Clinical Trial May 15, 2022

AUA 2022: Adverse Events Related to Darolutamide Treatment: Analysis of “Real Life” Data From EudraVigilance and the FDA Database Entries May 15, 2022

AUA 2022: Concomitant vs Staged Lymphadenectomy in Clinically Node-Positive Penile Squamous Cell Carcinoma: Recurrence Patterns and Survival Outcomes May 15, 2022

AUA 2022: Survival in N3 Penile Cancer: Does Pelvic Lymphadenopathy Predict a Worse Prognosis than Inguinal Extra-Nodal Extension? May 15, 2022

AUA 2022: Response Rates and Survival Outcomes of Metastasis Directed Therapies in Solitary Oligo-recurrent Prostate Cancer May 15, 2022

AUA 2022: The Role of 68Ga-PSMA- and 68Ga-DOTA-RM2 PET/MRI in the Primary Staging of High-Risk Prostate Cancer Patients Undergoing Radical Prostatectomy. Preliminary Results of a Prospective, Single Center Study May 15, 2022

AUA 2022: Optimizing Timing And Indications For 68Ga-PSMA PET/CT In Patients With Biochemical Recurrent Prostate Cancer After Radical Prostatectomy May 15, 2022

AUA 2022: The Key Role Of Concomitant ADT On The Efficacy Of Imaging Guided Treatments In Men With Biochemical Recurrent Prostate Cancer After Radical Prostatectomy And Positive 68Ga-PSMA PET/CT Scan May 15, 2022

AUA 2022: Evaluating Cardiovascular Risk in Men Starting Androgen Deprivation Therapy for Prostate Cancer May 15, 2022

AUA 2022: Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis May 15, 2022

AUA 2022: Interim Results From a Phase 1B Clinical Trial Evaluating Tolerability and Activity of FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma May 15, 2022

AUA 2022: Trends of Primary Staging for Newly Diagnosed Prostate Cancer – Assessing the Uptake of Prostate Specific Membrane Antigen Positron Emission Tomography: A Population Based Analysis May 15, 2022

AUA 2022: Demographics and Socioeconomic Description of Patients with Prostate Cancer in Whom a Prostate-Specific Membrane Antigen PET Was Performed: A Single-Institution, Retrospective Analysis in NYC May 15, 2022

AUA 2022: The Risk of Recurrence in cN1 Prostate Cancer Patients Treated with Radical Prostatectomy Varies According to the Type Preoperative Staging. a Comparison Between 68Ga-PSMA-PET Versus Conventional Imaging in a Large, Multi-Institutional Study May 15, 2022

AUA 2022: Interim Analysis: IV Vitamin C with Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients May 15, 2022

AUA 2022: Medium to Long Term Health-Related QoL and Treatment-Related Side-Effects in Patients Treated with a Single Dose of Adjuvant Carboplatin for High-risk Seminoma – Results From a Pilot Study May 15, 2022

AUA 2022: Contemporary Surgical Outcomes of Retroperitoneal Lymph Node Dissection From the SEMS Trial May 15, 2022

Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting May 15, 2022

AUA 2022: Clinical Measurement of Maximum Achievable Ureteral Internal Circumference Using a Novel Force Sensor May 15, 2022

AUA 2022: Active Surveillance for Low-Risk Prostate Cancer: Time Trends and Variation in the AUA Quality (AQUA) Registry May 15, 2022

Page 12 of 472

email news signup